Bone marrow

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Retrieved on: 
Friday, March 22, 2024
Bone marrow, Conference, Therapy

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.

Key Points: 
  • HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.
  • This conference will be held virtually on March 26, 2024.
  • Dr. Vera will present an overview of Marker’s advancements and clinical development programs on Tuesday, March 26, 2024, at 10 AM EDT.
  • Details of the presentation are as follows:

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Retrieved on: 
Thursday, March 21, 2024
ACT, Gene silencing, Metabolism, Conference, Immunotherapy, CD25, CD98, Compound, RNA interference, Bone marrow, Poster, NK, Chronic myelogenous leukemia, Pharmaceutical industry

The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.

Key Points: 
  • The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation.
  • These preclinical data demonstrate the potential of INTASYL Compound PH-905 to improve Adoptive Cell Therapy (ACT) by targeting and silencing Cbl-b.
  • This may result in a more effective cell therapy for hematological malignancies.
  • INTASYL compound PH-905 may be used to improve the anti-tumor response of NK cells to provide a more effective cell therapy for cancer treatment.

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Retrieved on: 
Wednesday, March 20, 2024
Encephalitis, ICER, Bone marrow, Patient, DSM-IV codes, Urinary tract infection, Travel, Child, Health technology assessment, Therapy, Children's Hospital of Philadelphia, Central nervous system, Risk, MLD, Qualification, Health, WAC, NBS, Nerve, Mutation, UCSF, Disease, Federation, Research, Acquisition, Genome, Rash, Stem cell, HSC, Hospital, Family, Swelling, FDA, Diagnosis, HTA, Caregiver, Traffic barrier, Viral, Fever, Kyowa Kirin, PSLI, Liver, Government, San Raffaele Hospital, ARSA, Pharmaceutical industry

TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile, (PSEJ), or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).

Key Points: 
  • Prior to Lenmeldy, there were no treatment options in the U.S. for early-onset MLD beyond supportive and end-of-life care.
  • This approach has the potential to restore enzymatic function to stop or slow disease progression with a single treatment.
  • Utilizing results from such studies, a multi-stakeholder working group is finalizing a nomination to add MLD to the U.S.
  • Based on current timelines and assumptions, Orchard Therapeutics expects the nomination will be submitted in mid-year 2024.

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Research, LAVA, AML, Risk, Patient, Acute myeloid leukemia, CRS, Syndrome, Cancer, Completeness, Pembrolizumab, IND, DLT, Investment, Bone marrow, Infrared spectroscopy correlation table, Premedication, CD123, MDS, Cytokine release syndrome

LAVA 1207 – In Phase 1/2a -- Next update expected H2 2024 targeting a medical conferenceDesigned to mediate potent killing of prostate-specific membrane antigen (PSMA)-positive prostate cancer cells

Key Points: 
  • LAVA-1207 has enrolled dose level 9 in our Phase 1/2a trial of patients with metastatic castration-resistant prostate cancer (mCRPC).
  • We continue to be encouraged by the favorable safety profile and preliminary signs of anti-tumor activity.
  • We plan to provide new data for LAVA-1207 at an upcoming medical conference in the second half of 2024,” said Stephen Hurly, President and Chief Executive Officer of LAVA.
  • “These advances represent important steps for our proprietary Gammabody® T-cell engagers as we evaluate their potential to treat cancer.

NMDP Receives Record-Breaking $5 Million Philanthropic Gift

Retrieved on: 
Tuesday, March 19, 2024
Patient, Bone marrow, Research, NMDP, Pharmaceutical industry

A portion of the $5 million will fund recruitment, to continue adding young, ethnically diverse members to the NMDP Registry, the world’s most diverse registry of blood stem cell or marrow donors.

Key Points: 
  • A portion of the $5 million will fund recruitment, to continue adding young, ethnically diverse members to the NMDP Registry, the world’s most diverse registry of blood stem cell or marrow donors.
  • Another part of the gift will support patient financial assistance, the number one patient-reported barrier to transplant.
  • “With the Moore family’s generous contribution to NMDP, good goes a long way in advancing our mission, and we are extremely grateful.
  • Thanks in part to philanthropic gifts, NMDP has made monumental strides in accelerating progress and expanding access to treatment.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Multiple myeloma, Pregnancy, Organization, Bone marrow, Development, Strategic planning, Disease, Patient, Celanese, Research, Cancer, University, IMF, Volunteering, Quality of life, United Way, Marketing, Woman, Black swan, International Myeloma Foundation, Thalidomide, MRD, International business, Loyola University Chicago, BSRI, Loyola University, Kellogg School of Management

STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.

Key Points: 
  • STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.
  • Prior to his recent election, John served on the IMF Board from 2010-2016 and made many significant contributions to advance the mission and goals of the IMF.
  • A cure is possible, but it is not free!”
    “I am thrilled to have John back on the IMF Board.
  • “I am very excited to welcome board member John O’Dwyer back to the IMF Board.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Retrieved on: 
Wednesday, March 13, 2024
Lung cancer, Pollination, Bee, Metabolism, Culture, Gene, Algorithm, National Medal, Brain, Growth, Aditi, Gene expression, Survival, Cell, Bone marrow, Trustee, School, Research, Science News, RET, Highlands Ranch, Colorado, Death, Macrophage, ARD International Music Competition, Society, Student, Thought, Nobel Prize, STEM, CO, Cancer, MYC, ChatGPT, Machine learning, Society for Science, Liver, STS, Pharmaceutical industry

The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.

Key Points: 
  • The 2024 finalists demonstrated extensive scientific knowledge through research and interviews while showcasing their commitment to addressing societal issues, passion for discovery, noteworthy leadership and community involvement.
  • This knowledge sheds light on what these algorithms are “thinking,” which can help make them more effective, fair and safe.
  • “Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • In total, Regeneron awarded $3.1 million in prizes through the Regeneron Science Talent Search 2024, including $2,000 to each of the top 300 scholars and their schools.

SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Retrieved on: 
Tuesday, March 12, 2024
XRT, ASH, Patient, PTCL, City, Tumor microenvironment, NHL, CTCL, Society, Safety, Bone marrow, Poster

“The culmination of years of development work, initially in Academia, and later taken forward by SIRPant, we are pleased to announce the dosing of the first patient in this Phase 1 study evaluating SIRPant-M™, last week at the City of Hope Cancer Center.”, said Jelle Kijlstra, M.D., Chief Medical Officer of SIRPant.

Key Points: 
  • “The culmination of years of development work, initially in Academia, and later taken forward by SIRPant, we are pleased to announce the dosing of the first patient in this Phase 1 study evaluating SIRPant-M™, last week at the City of Hope Cancer Center.”, said Jelle Kijlstra, M.D., Chief Medical Officer of SIRPant.
  • The interaction of immune cells in the tumor microenvironment influences progression of cutaneous T cell lymphoma,” said Christiane Querfeld, M.D., Ph.D., Director of the Multidisciplinary Cutaneous Lymphoma Program, and one of the principal investigators of the study.
  • Both B-cell and certain T-cell NHL (select PTCL; CTCL) are eligible.
  • The primary objective of the study is to assess the safety and tolerability of autologous SIRPant-M™.